Literature DB >> 16359671

Differential beta-arrestin binding of AT1 and AT2 angiotensin receptors.

Gábor Turu1, László Szidonya, Zsuzsanna Gáborik, László Buday, András Spät, Adrian J L Clark, László Hunyady.   

Abstract

Agonist stimulation of G protein-coupled receptors causes receptor activation, phosphorylation, beta-arrestin binding and receptor internalization. Angiotensin II (AngII) causes rapid internalization of the AT1 receptors, whereas AngII-bound AT2 receptors do not internalize. Although the activation of the rat AT1A receptor with AngII causes translocation of beta-arrestin2 to the receptor, no association of this molecule with the AT2 receptor can be detected after AngII treatment with confocal microscopy or bioluminescence resonance energy transfer. These data demonstrate that the two subtypes of angiotensin receptors have different mechanisms of regulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16359671     DOI: 10.1016/j.febslet.2005.11.044

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Paracrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptors.

Authors:  Gábor Turu; Péter Várnai; Pál Gyombolai; László Szidonya; László Offertaler; György Bagdy; George Kunos; László Hunyady
Journal:  J Biol Chem       Date:  2009-04-07       Impact factor: 5.157

3.  Mapping of the localization of type 1 angiotensin receptor in membrane microdomains using bioluminescence resonance energy transfer-based sensors.

Authors:  András Balla; Dániel J Tóth; Eszter Soltész-Katona; Gyöngyi Szakadáti; László Sándor Erdélyi; Péter Várnai; László Hunyady
Journal:  J Biol Chem       Date:  2012-01-30       Impact factor: 5.157

4.  Investigation of the fate of type I angiotensin receptor after biased activation.

Authors:  Gyöngyi Szakadáti; András D Tóth; Ilona Oláh; László Sándor Erdélyi; Tamas Balla; Péter Várnai; László Hunyady; András Balla
Journal:  Mol Pharmacol       Date:  2015-03-24       Impact factor: 4.436

5.  Acute depletion of plasma membrane phosphatidylinositol 4,5-bisphosphate impairs specific steps in endocytosis of the G-protein-coupled receptor.

Authors:  Dániel J Tóth; József T Tóth; Gergö Gulyás; András Balla; Tamas Balla; László Hunyady; Péter Várnai
Journal:  J Cell Sci       Date:  2012-02-22       Impact factor: 5.285

6.  Klotho Ameliorates Medullary Fibrosis and Pressure Natriuresis in Hypertensive Rat Kidneys.

Authors:  Tsuneo Takenaka; Tsutomu Inoue; Takashi Miyazaki; Hiroyuki Kobori; Akira Nishiyama; Naohito Ishii; Matsuhiko Hayashi; Hiromichi Suzuki
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

7.  The effect of angiotensin II and IV on ERK1/2 and CREB signalling in cultured rat astroglial cells.

Authors:  Adam Holownia; Jan J Braszko
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-19       Impact factor: 3.000

8.  Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.

Authors:  László Sándor Erdélyi; András Balla; Attila Patócs; Miklós Tóth; Péter Várnai; László Hunyady
Journal:  Mol Endocrinol       Date:  2014-03-14

Review 9.  Angiotensin II Type 2 Receptor: A Target for Protection Against Hypertension, Metabolic Dysfunction, and Organ Remodeling.

Authors:  Naureen Fatima; Sanket N Patel; Tahir Hussain
Journal:  Hypertension       Date:  2021-04-12       Impact factor: 10.190

10.  Receptor-Heteromer Investigation Technology and its application using BRET.

Authors:  Elizabeth K M Johnstone; Kevin D G Pfleger
Journal:  Front Endocrinol (Lausanne)       Date:  2012-08-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.